Silence Therapeutics plc
(Public, LON:SLN) Watch this stockFind more results forSLN
Events
Sep 30, 2009
Interim 2009 Earnings Release
Sep 14, 2009
ANNUAL BIOTECH IN EUROPE INVESTOR FORUM
|
|
Key stats and ratios
| Q2 (Jun '09) | 2008 | |
| Net profit margin | -416.92% | -336.53% |
| Operating margin | -421.47% | -352.69% |
| EBITD margin | - | -333.54% |
| Return on average assets | -52.80% | -43.92% |
| Return on average equity | -56.49% | -47.78% |
| Employees | 51 | - |
Address
21 Albemarle Street
London, ENG W1S 4BS
United Kingdom - Map
+44-20-74916520 (Phone)
+44-20-74916521 (Fax)
London, ENG W1S 4BS
United Kingdom - Map
+44-20-74916520 (Phone)
+44-20-74916521 (Fax)
Website links
Company website:
http://www.silence-therapeutics.com...
http://www.silence-therapeutics.com...
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Silence Therapeutics plc discussions
View all discussions »Description
Silence Therapeutics plc (Silence Therapeutics) is engaged in the research and development of pharmaceutical products. In particular the Company is focusing on the development of its ribonucleic acid interference (RNAi) technology, which is moving from the pre-clinical into clinical development phase. Its subsidiaries include Silence Therapeutics AG, Stanford Rook Ltd and Innopeg Ltd.
Officers and directors
| Iain G. Ross | Chairman of the Board, Group Chief Executive Officer | |
| J. Melvyn Davies | Finance Director, Company Secretary, Executive Director | |
| Thomas Christely | Chief Operating Officer | |
| John Lucas | Vice President - Intellectual Property, General Counsel | |
| Klaus Giese Ph.D. | Chief Scientific Officer | |
| H. R. Peter Reynolds | Non-Executive Director | |
| David C. U'Prichard Ph.D. | Non-Executive Director | |
| Bernd O. Wetzel Ph.D. | Non-Executive Director | |
| Annette Clancy | Non-Executive Director | |
| Jerry A.P. Randall | Non-Executive Director |